Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, CA 94158
March 2, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549
| Attention: | Tim Buchmiller |
| Re: | Nurix Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-253783) originally filed March 2, 2021. |
Requested Date: March 4, 2021
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Nurix Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Michael A. Brown or Amanda L. Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Brown at (415) 875-2432 or, in his absence, Ms. Rose at (206) 389-4553.
* * *
| Sincerely, | ||
| NURIX THERAPEUTICS, INC. | ||
| By: | /s/ Hans van Houte | |
| Hans van Houte | ||
| Chief Financial Officer | ||
| cc: | Arthur T. Sands, President and Chief Executive Officer |
Christine Ring, General Counsel
Nurix Therapeutics, Inc.
Michael A. Brown, Esq.
Amanda L. Rose, Esq.
Robert A. Freedman, Esq.
Jennifer J. Hitchcock, Esq.
Fenwick & West LLP